4-Chlorokynurenine
Investigational antidepressant compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about 4-Chlorokynurenine?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
L-4-Chlorokynurenine (4-Cl-KYN; developmental code name AV-101) is an orally active small molecule prodrug of 7-chlorokynurenic acid, a NMDA receptor antagonist. It was investigated as a potential rapid-acting antidepressant.
Quick Facts Clinical data, Other names ...
Clinical data | |
---|---|
Other names | 4-Cl-KYN; AV-101; 3-(4-Chloroanthraniloyl)-DL-alanine |
Routes of administration | By mouth |
Drug class | NMDA receptor antagonist |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 39–84% (rodents); ≥ 31% (humans)[citation needed] |
Elimination half-life | 2–3 hours[citation needed] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H11ClN2O3 |
Molar mass | 242.66 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
AV-101 was discovered at Marion Merrell Dow and its biological activity was explored at University of Maryland. It underwent initial development at Artemis Neuroscience which was acquired by VistaGen in 2003. A phase II clinical trial failed to show any effect over placebo in alleviating treatment-resistant depression.[1]